Capricor Therapeutics, Inc. (NASDAQ: CAPR) reported a significant insider transaction involving Karen Krasney, the company's Executive Vice President and General Counsel. On June 25, 2026, Krasney executed the sale of 24,100 shares of the company's common stock. The total value of these shares reached $732,158 at the time of the transaction.
The sale was directly linked to the exercise of stock options. Krasney acquired the 24,100 shares through option exercises, paying an exercise price of $3.18 per share. This initial acquisition cost totaled $76,638. The options in question vested according to a schedule of 1/48th of the total on the first day of each month, starting from February 1, 2022. Immediately upon acquiring these shares, Krasney sold all 24,100 shares. The shares were sold at prices ranging from $30.00 to $30.88, with a weighted average price of $30.38 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan that was adopted in December 2025.
Following the completion of these transactions, Krasney directly holds 30,547 shares of Capricor Therapeutics common stock. The company's stock currently trades at $23.80, which is down from the $30+ range where Krasney executed her sale. According to InvestingPro analysis, CAPR has delivered a remarkable 140% return over the past year despite recent volatility. The platform's Fair Value analysis suggests the stock is trading near its intrinsic value. Investors can access comprehensive insights through the Pro Research Report, one of 1,400+ available for US equities, alongside additional ProTips for deeper analysis.
In other recent developments, Capricor Therapeutics reported a larger-than-expected loss for the first quarter of 2026. The company reported an earnings per share (EPS) of -$0.59, compared to the anticipated -$0.52, marking a 13.46% miss. Despite this earnings shortfall, the company maintains a strong financial position, with enough cash to support operations until the fourth quarter of 2027.
Additionally, Capricor's lead product, deramiocel, is currently under active review by the U.S. Food and Drug Administration (FDA). The FDA has scheduled an advisory committee meeting on July 29, 2026, to discuss the Biologics License Application for deramiocel, supported by data from the company's various trials. Capricor also presented five-year data from its HOPE-2 Open-Label Extension study at a recent conference. Meanwhile, B.Riley has maintained a Buy rating and a $63 price target on Capricor, citing updates on legal, regulatory, and commercial matters. The company has filed a rescission against Nippon Shinyaku and NS Pharma, adding to the ongoing developments.
The stock currently trades at $23.80, down from the $30+ range where Ms. Krasney executed her sale. According to InvestingPro analysis, CAPR has delivered a remarkable 140% return over the past year despite recent volatility. The platform's Fair Value analysis suggests the stock is trading near its intrinsic value, and investors can access comprehensive insights through the Pro Research Report, one of 1,400+ available for US equities, alongside additional ProTips for deeper analysis.